News & Highlights

Siamo particolarmente orgogliosi di comunicare che Doppel è stata inserita tra le 275 aziende italiane che puntano sui valori della diversità e dell’inclusione, secondo la classifica stilata da Il Sole 24 Ore in collaborazione con Statista. Questo riconoscimento corona un percorso iniziato qualche tempo fa e rappresenta un ulteriore punto di partenza per nuove sfide nell'ambito più ampio della "sostenibilità". Rispetto della diversità, equità e pari opportunità rappresentano, [...]

Milan, 23rd July 2024 An agreement was signed today between the international investment fund Trilantic Europe and the Italian investment fund Alto Capital IV, managed by Alto Partners SGR, to achieve the aggregation of the industrial centers for third-party pharmaceutical production Doppel Farmaceutici and Mipharm. The companies will merge into a new industrial entity, controlled by Trilantic Europe and Alto Capital IV with equal shares, [...]

Milano, 23 Luglio 2024 In data odierna è stato siglato un accordo tra il fondo di investimento internazionale Trilantic Europe e il fondo di investimento Italiano Alto Capital IV, gestito da Alto Partners SGR, per realizzare l’aggregazione dei poli industriali per la produzione farmaceutica conto terzi Doppel Farmaceutici e Mipharm. Le società confluiranno in un nuovo soggetto industriale, controllato da Trilantic Europe e Alto Capital [...]

Founded in 1994 as a spin-off of the Hoechst Roussel Group, Doppel Farmaceutici has grown to become one of the leading European CDMOs. What began with just over 40 employees has flourished into a robust team of over 600 highly skilled professionals. Our two large manufacturing facilities, located in Cortemaggiore (PC) and Rozzano (MI), work to produce over 700 pharmaceutical products, such as HP solids [...]

Rozzano, 31st January 2024. Doppel Pharma CDMO is delighted to announce the successful revamping of its Sterile Department (Ampoule) at the Rozzano plant (Milan), culminating in the receipt of AIFA approval in Jan 2024.  In late 2022, Doppel decided to upgrade its Milan based facility to align with stringent Annex 1 GMP Guidelines. Since then, Doppel collaborated with its customers to ensure continued availability of [...]

Doppel perspective on Orphan drugs According to the US Food and Drug Administration (FDA), an orphan drug is defined as one "intended for the treatment, prevention or diagnosis of a rare disease or condition, which is one that affects less than 200,000 people in the US" (which equates to approximately 6 cases per 10,000 of its population), "or meets cost recovery provisions of the act". [...]